Osvaldos vaistinė - Company finances
|
EUR
|
2020
From: 2020-08-12
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | - | 148,911 | 243,770 | 305,399 | 361,374 | 418,774 |
| Profit before tax | -10,416 | 28,762 | 28,975 | 36,261 | 15,034 | 38,068 |
| Net profit | -10,416 | 27,794 | 27,472 | 30,659 | 12,503 | 30,256 |
| Equity | -7,916 | 19,878 | 47,350 | 72,009 | 84,512 | 114,768 |
| Liabilities | 14,013 | 38,609 | 25,423 | 68,867 | 74,196 | 67,773 |
| Non-current assets | 0 | 0 | 6,813 | 6,063 | 8,313 | 38,148 |
| Current assets | 6,097 | 58,487 | 65,942 | 134,813 | 151,095 | 145,093 |
| Total assets | 6,097 | 58,487 | 72,755 | 140,876 | 159,408 | 183,241 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | 7,358 | 14,065 | 9,827 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | - | +63.7% | +25.3% | +18.3% | +15.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -170.8% | 47.5% | 37.8% | 21.8% | 7.8% | 16.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 139.8% | 58.0% | 42.6% | 14.8% | 26.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 18.7% | 11.3% | 10.0% | 3.5% | 7.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 19.3% | 11.9% | 11.9% | 4.2% | 9.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 1.9 | 0.5 | 1.0 | 0.9 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 148,911 | 243,770 | 305,399 | 361,374 | 418,774 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Osvaldos vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-06-16 | 2022-06-22 | 250.15 |
| 2022-03-16 | 2022-04-06 | 216.77 |
Osvaldos vaistinė - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-06-05 | 2026-06-05 | 1711.86 |
| 2026-06-04 | 2026-06-04 | 1711.4 |
| 2026-06-02 | 2026-06-03 | 1690.4 |
| 2025-05-20 | 2025-05-20 | 0.51 |
| 2025-05-08 | 2025-05-19 | 27.63 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Osvaldos vaistine, UAB (code 305602412) is a private limited liability company operating in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €418.8K, up 15.9% year on year and 37.1% over two years. Net profit amounted to €30.3K, after €12.5K in 2024 and €30.7K in 2023, showing that profitability weakened in 2024 and recovered in 2025. Profit margin improved to 7.2% in 2025 from 3.5% in 2024, though it remained below the 10.0% achieved in 2023. The balance sheet also strengthened: total assets rose to €183.2K, equity increased to €114.8K, and liabilities were €67.8K. The equity ratio stood at 62.6%, with debt-to-equity at 0.59. Asset turnover was 2.29x, supported by revenue per employee of €418.8K and profit per employee of €30.3K. Long-term assets increased to €38.1K in 2025, while short-term assets were €145.1K.